More than 100 years after the introduction of insulin therapy, the ability to dramatically reduce the number of injections needed provides a great opportunity to simplify insulin therapy in many people with type 2 diabetes (and possibly also in those with type 1 diabetes who find it hard to accept new technologies and who have poor adherence to therapy). This evidence concerns the gene INS and type 1 diabetes mellitus.